ALT Earnings & Financial Statements
Altimmune, Inc.
$2.31
-$0.12(-4.94%)
33
Overall
60
Value
--
Tech
39
Quality
Market Cap
$449.34M
Volume
5.63M
52W Range
$2.55 - $6.44
Target Price
$14.50
ALT earnings and financial statements: Altimmune, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ALT Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $41.0K | $20.0K | $426.0K | -$68.0K | $4.41M |
| Operating income | -$94.49M | -$103.17M | -$95.93M | -$87.74M | -$96.91M |
| EBITDA | -$86.67M | -$94.85M | -$87.95M | -$84.41M | -$96.53M |
| Net income | -$88.09M | -$95.06M | -$88.45M | -$84.71M | -$97.09M |
| EPS (diluted) | $-1.00 | $-1.34 | $-1.66 | $-1.81 | $-2.35 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $279.93M | $139.31M | $210.64M | $206.93M | $218.87M |
| Total liabilities | $55.04M | $15.80M | $16.54M | $21.64M | $19.73M |
| Shareholders’ equity | $224.89M | $123.51M | $194.10M | $185.29M | $199.13M |
| Cash and equivalents | $43.76M | $36.93M | $135.12M | $111.10M | $190.30M |
| Long-term debt | $34.29M | $1.40M | - | $4.58M | $1.45M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$67.53M | -$79.85M | -$75.81M | -$62.59M | -$78.24M |
| Capital expenditure | -$11.0K | - | -$47.0K | -$126.0K | -$12.31M |
| Free cash flow | -$67.55M | -$79.85M | -$75.86M | -$62.71M | -$90.55M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ALT | $2.31 | -4.9% | 5.63M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |